CASI Files for Fourth China Trial of Lead Cancer Drug

CASI Pharma, a US-China biopharma, filed for CFDA approval to begin a China Phase II clinical trial of its lead novel drug candidate, ENMD-2076, in patients with fibrolamellar carcinoma (FLC). The trial is an extension of a similar US trial. CASI has already started a three other US-China Phase II tests of the drug for various forms of cancer. Headquartered in Maryland with a lab in Beijing, CASI in-licenses products for the China market, but is developing ENMD-2076 globally. More details.... Stock Symbol: (NSDQ: CASI) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.